CVE:COV

Covalon Technologies Competitors

C$1.55
+0.05 (+3.33 %)
(As of 04/20/2021 11:06 AM ET)
Add
Compare
Today's Range
C$1.50
Now: C$1.55
C$1.55
50-Day Range
C$1.32
MA: C$1.46
C$1.76
52-Week Range
C$0.70
Now: C$1.55
C$1.99
Volume985 shs
Average Volume5,820 shs
Market CapitalizationC$40.02 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Covalon Technologies (CVE:COV) Vs. IPA, HBP, ACST, NVH, MBX, and PDP

Should you be buying COV stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Covalon Technologies, including ImmunoPrecise Antibodies (IPA), Helix BioPharma (HBP), Acasti Pharma (ACST), Novoheart (NVH), Microbix Biosystems (MBX), and Pediapharm (PDP).

Covalon Technologies (CVE:COV) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Covalon Technologies and ImmunoPrecise Antibodies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Covalon Technologies0000N/A
ImmunoPrecise Antibodies0000N/A

Earnings and Valuation

This table compares Covalon Technologies and ImmunoPrecise Antibodies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Covalon TechnologiesC$23.84 million1.68C$-6,144,922.00C($0.24)-6.51
ImmunoPrecise AntibodiesC$17.18 million13.08C$-4,082,906.00C($0.21)-55.05

ImmunoPrecise Antibodies has lower revenue, but higher earnings than Covalon Technologies. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Covalon Technologies and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Covalon TechnologiesN/AN/AN/A
ImmunoPrecise AntibodiesN/AN/AN/A

Summary

ImmunoPrecise Antibodies beats Covalon Technologies on 3 of the 5 factors compared between the two stocks.

Covalon Technologies (CVE:COV) and Helix BioPharma (TSE:HBP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Covalon Technologies and Helix BioPharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Covalon Technologies0000N/A
Helix BioPharma0000N/A

Earnings and Valuation

This table compares Covalon Technologies and Helix BioPharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Covalon TechnologiesC$23.84 million1.68C$-6,144,922.00C($0.24)-6.51
Helix BioPharmaN/AN/AN/AC($0.06)-16.00

Helix BioPharma has lower revenue, but higher earnings than Covalon Technologies. Helix BioPharma is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Covalon Technologies and Helix BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Covalon TechnologiesN/AN/AN/A
Helix BioPharmaN/AN/AN/A

Summary

Covalon Technologies beats Helix BioPharma on 2 of the 3 factors compared between the two stocks.

Covalon Technologies (CVE:COV) and Acasti Pharma (CVE:ACST) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Covalon Technologies and Acasti Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Covalon Technologies0000N/A
Acasti Pharma0000N/A

Earnings and Valuation

This table compares Covalon Technologies and Acasti Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Covalon TechnologiesC$23.84 million1.68C$-6,144,922.00C($0.24)-6.51
Acasti PharmaC$81,000.001,334.13C$6.80 millionC$0.0315.88

Acasti Pharma has lower revenue, but higher earnings than Covalon Technologies. Covalon Technologies is trading at a lower price-to-earnings ratio than Acasti Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Covalon Technologies and Acasti Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Covalon TechnologiesN/AN/AN/A
Acasti PharmaN/AN/AN/A

Summary

Acasti Pharma beats Covalon Technologies on 4 of the 5 factors compared between the two stocks.

Covalon Technologies (CVE:COV) and Novoheart (CVE:NVH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Covalon Technologies and Novoheart, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Covalon Technologies0000N/A
Novoheart0000N/A

Earnings and Valuation

This table compares Covalon Technologies and Novoheart's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Covalon TechnologiesC$23.84 million1.68C$-6,144,922.00C($0.24)-6.51
NovoheartC$423,500.00236.08C$-7,168,358.00C($0.04)-13.95

Covalon Technologies has higher revenue and earnings than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Covalon Technologies and Novoheart's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Covalon TechnologiesN/AN/AN/A
NovoheartN/AN/AN/A

Summary

Covalon Technologies beats Novoheart on 3 of the 5 factors compared between the two stocks.

Covalon Technologies (CVE:COV) and Microbix Biosystems (TSE:MBX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Covalon Technologies and Microbix Biosystems, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Covalon Technologies0000N/A
Microbix Biosystems0000N/A

Earnings and Valuation

This table compares Covalon Technologies and Microbix Biosystems' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Covalon TechnologiesC$23.84 million1.68C$-6,144,922.00C($0.24)-6.51
Microbix BiosystemsC$11.64 million5.55C$-5,581,797.00C($0.05)-11.57

Microbix Biosystems has lower revenue, but higher earnings than Covalon Technologies. Microbix Biosystems is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Covalon Technologies and Microbix Biosystems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Covalon TechnologiesN/AN/AN/A
Microbix BiosystemsN/AN/AN/A

Summary

Microbix Biosystems beats Covalon Technologies on 3 of the 5 factors compared between the two stocks.

Covalon Technologies (CVE:COV) and Pediapharm (CVE:PDP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Analyst Ratings

This is a summary of current recommendations and price targets for Covalon Technologies and Pediapharm, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Covalon Technologies0000N/A
Pediapharm0000N/A

Valuation and Earnings

This table compares Covalon Technologies and Pediapharm's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Covalon TechnologiesC$23.84 million1.68C$-6,144,922.00C($0.24)-6.51
PediapharmC$11.16 million5.95C$-16,147,162.00C($0.07)-4.11

Covalon Technologies has higher revenue and earnings than Pediapharm. Covalon Technologies is trading at a lower price-to-earnings ratio than Pediapharm, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Covalon Technologies and Pediapharm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Covalon TechnologiesN/AN/AN/A
PediapharmN/AN/AN/A

Summary

Pediapharm beats Covalon Technologies on 3 of the 5 factors compared between the two stocks.


Covalon Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
IPA
ImmunoPrecise Antibodies
0.4$11.78+3.7%C$123.03 millionC$17.18 million-55.05
HBP
Helix BioPharma
0.5$0.88+2.3%C$119.96 millionN/A-16.00Gap Up
ACST
Acasti Pharma
0.8$0.54+1.9%C$88.79 millionC$81,000.0015.88News Coverage
NVH
Novoheart
0.5$0.53+1.9%C$79.23 millionC$423,500.00-13.95
MBX
Microbix Biosystems
0.9$0.59+3.4%C$66.76 millionC$11.64 million-11.57News Coverage
PDP
Pediapharm
0.5$0.30+1.7%C$66.36 millionC$11.16 million-4.11
SBM
Sirona Biochem
0.5$0.33+4.5%C$58.80 millionC$123,870.00-25.38
PMN
ProMIS Neurosciences
0.5$0.19+2.7%C$55.07 millionC$1,787.00-9.25News Coverage
Gap Up
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.25+2.0%C$34.02 millionC$13.02 million-0.36Gap Up
IGX
IntelGenx Technologies
0.9$0.55+1.8%C$30.87 millionC$1.54 million-6.79
QPT
Quest PharmaTech
0.8$0.11+13.6%C$21.76 millionC$38,871.000.17Gap Down
CZO
Ceapro
0.7$0.74+1.4%C$21.65 millionC$16.14 million22.42
CTX
Crescita Therapeutics
0.6$0.80+6.3%C$16.52 millionC$15.64 million400.00
KNE
Kane Biotech
0.4$0.20+2.6%C$14.12 millionC$1.34 million-5.57
GSD
Devonian Health Group
0.5$0.26+3.8%C$13.96 millionC$1.59 million-5.42High Trading Volume
PAS
Pascal Biosciences
0.6$0.08+0.0%C$12.70 millionN/A-3.64
NSP
Naturally Splendid Enterprises
0.6$0.06+0.0%C$11.06 millionC$2.03 million-1.40
MPH
Medicure
0.7$1.63+1.2%C$10.80 millionC$12.71 million-1.05Gap Up
BTI
Bioasis Technologies
0.7$0.34+1.5%C$10.16 millionC$4.12 million30.45Gap Down
HEM
Hemostemix
0.6$0.33+6.2%C$9.07 millionN/A-1.93Gap Down
ICO
iCo Therapeutics
0.5$0.11+0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.38+2.6%C$6.94 millionC$5.60 million7.04
IOT
Innovotech
0.8$0.17+5.9%C$6.52 millionC$1.04 million85.00Gap Down
BCT
BriaCell Therapeutics
0.5$3.61+5.8%C$4.48 millionN/A-1.17
RVV
Revive Therapeutics
0.5$0.08+12.5%C$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04+71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03+16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01+0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$46.76+1.7%C$0.00C$267.59 million51.38
LTY
Liberty Biopharma
0.6$2.00+100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
SCYB
Scythian Biosciences
0.5$3.49+6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32+5.3%C$0.00N/A0.00News Coverage
Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.